Showing results (241-250 of 432) with videos related to
Sort By:
Pageof 44
Leukemia Research|June 1, 2012
Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trialXavier Thomas, Emmanuel Raffoux, Aline Renneville, et al.Haematologica|April 10, 2025
Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS RegistryBente Houtman, Adele Taylor, Corine Van Marrewijk, et al.Oncotarget|May 18, 2017
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemiaValérie Vidal, Guillaume Robert, Laure Goursaud, et al.Blood|April 9, 2015
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemiaDorothée Selimoglu-Buet, Orianne Wagner-Ballon, Véronique Saada, et al.British Journal of Haematology|February 18, 2026
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategiesAleksandar Savic, Adele Taylor, Pierre Fenaux, et al.Oncotarget|February 5, 2011
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndromeEmmanuel Raffoux, Audrey Cras, Christian Recher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia GroupLionel Adès, Sylvie Chevret, Emmanuel Raffoux, et al.The Lancet. Oncology|February 24, 2009
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyPierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, et al.Blood|March 22, 2003
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupJacques Delaunay, Norbert Vey, Thierry Leblanc, et al.American Journal of Hematology|April 9, 2013
Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patientsLionel Adès, Sylvie Chevret, Emmanuel Raffoux, et al.Pageof 44